Loading
OncoSTING
OncoSTING is developing OS-151, a modified form of the BCG bladder treatment that also releases a strong immune-activating molecule, for bladder cancer. It is in laboratory testing.
Also called: OncoSTING LLCONCOSTING LLC
Overview
OncoSTING develops recombinant BCG immunotherapies engineered for sustained release of STING agonists. Its lead, OS-151, is a second-generation BCG that produces high levels of a STING agonist while keeping the activity of traditional BCG, aimed at non-muscle invasive bladder cancer and, as an intratumoral therapy, other solid tumours; the company reports it was more effective and better tolerated than traditional BCG in preclinical models. In fiscal year 2026 NCI awarded it USD 1,030,215 under SBIR award 1R44CA310037-01 for STING agonist-expressing BCG in bladder cancer.
Headquarters
Baltimore, MD, US
Scorecard
All companies#789of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 1R44CA310037-01: STING agonist-expressing BCG to enhance bladder cancer therapy | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalRecombinant BCG immunotherapy
OS-151 is an experimental modified BCG from OncoSTING for bladder cancer, built to release an immune-activating molecule. It is in laboratory testing.
Notes
- Read on oncosting.com and NIH RePORTER on 4 November 2026.
Connected
5Similar pages
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- CompanyTARIS Biomedical
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- TrialTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- TrialA Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- TrialA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- IdeaTrain the bone marrow to make better anti-tumour immune cells
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- TrialSunRISe-1
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
cancers
fronts
technologies
drugs
PreclinicalRecombinant BCG immunotherapy
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
oncosting.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/